APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

TNF Inhibitors for the Treatment of Plaque Psoriasis

Compare research editions
View pricing & licenses

Selected research

Industry Research

TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Research Report 2026

Report ID 174041650527 December 2025130 pages

Choose your research edition.

Industry ResearchTNF Inhibitors for the Treatment of Plaque Psoriasis Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal TNF Inhibitors for the Treatment of Plaque Psoriasis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal TNF Inhibitors for the Treatment of Plaque Psoriasis Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal TNF Inhibitors for the Treatment of Plaque Psoriasis Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global TNF Inhibitors for the Treatment of Plaque Psoriasis market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for TNF Inhibitors for the Treatment of Plaque Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for TNF Inhibitors for the Treatment of Plaque Psoriasis is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for TNF Inhibitors for the Treatment of Plaque Psoriasis is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of TNF Inhibitors for the Treatment of Plaque Psoriasis include Chia Tai Tianqing Pharmaceutical, Innovent Biologics, Sino Cell Technologies, Samsung Bioepis, Hangzhou Bozhirui Biopharmaceuticals, Hisun Pharmaceuticals, Bio-Thera Solutions, YL Biologics and UCB, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global TNF Inhibitors for the Treatment of Plaque Psoriasis market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

TNF Inhibitors for the Treatment of Plaque Psoriasis Market by Company

Chia Tai Tianqing Pharmaceutical

Innovent Biologics

Sino Cell Technologies

Samsung Bioepis

Hangzhou Bozhirui Biopharmaceuticals

Hisun Pharmaceuticals

Bio-Thera Solutions

YL Biologics

UCB

Teva

Sandoz

Pfizer

Janssen Biotech

Coherus BioSciences

Celltrion

Boehringer Ingelheim Pharmaceuticals

Biocon Biologics

Amgen

AbbVie

TNF Inhibitors for the Treatment of Plaque Psoriasis Segment by Type

Adalimumab

Certolizumab pegol

Etanercept

Infliximab

Other

TNF Inhibitors for the Treatment of Plaque Psoriasis Segment by Application

Hospital and Clinic

Retail Pharmacies

Other

TNF Inhibitors for the Treatment of Plaque Psoriasis Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global TNF Inhibitors for the Treatment of Plaque Psoriasis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of TNF Inhibitors for the Treatment of Plaque Psoriasis and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of TNF Inhibitors for the Treatment of Plaque Psoriasis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of TNF Inhibitors for the Treatment of Plaque Psoriasis manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of TNF Inhibitors for the Treatment of Plaque Psoriasis by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of TNF Inhibitors for the Treatment of Plaque Psoriasis in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units) of Manufacturers (2021-2026) Table 7. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Manufacturers (2021-2026) Table 8. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue of Manufacturers (2021-2026) Table 9. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Share by Manufacturers (2021-2026) Table 10. Global Market TNF Inhibitors for the Treatment of Plaque Psoriasis Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of TNF Inhibitors for the Treatment of Plaque Psoriasis, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of TNF Inhibitors for the Treatment of Plaque Psoriasis, Product Type & Application Table 14. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global TNF Inhibitors for the Treatment of Plaque Psoriasis by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Chia Tai Tianqing Pharmaceutical Company Information Table 19. Chia Tai Tianqing Pharmaceutical Business Overview Table 20. Chia Tai Tianqing Pharmaceutical TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Chia Tai Tianqing Pharmaceutical TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 22. Chia Tai Tianqing Pharmaceutical Recent Developments Table 23. Innovent Biologics Company Information Table 24. Innovent Biologics Business Overview Table 25. Innovent Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Innovent Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 27. Innovent Biologics Recent Developments Table 28. Sino Cell Technologies Company Information Table 29. Sino Cell Technologies Business Overview Table 30. Sino Cell Technologies TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Sino Cell Technologies TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 32. Sino Cell Technologies Recent Developments Table 33. Samsung Bioepis Company Information Table 34. Samsung Bioepis Business Overview Table 35. Samsung Bioepis TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Samsung Bioepis TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 37. Samsung Bioepis Recent Developments Table 38. Hangzhou Bozhirui Biopharmaceuticals Company Information Table 39. Hangzhou Bozhirui Biopharmaceuticals Business Overview Table 40. Hangzhou Bozhirui Biopharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Hangzhou Bozhirui Biopharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 42. Hangzhou Bozhirui Biopharmaceuticals Recent Developments Table 43. Hisun Pharmaceuticals Company Information Table 44. Hisun Pharmaceuticals Business Overview Table 45. Hisun Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Hisun Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 47. Hisun Pharmaceuticals Recent Developments Table 48. Bio-Thera Solutions Company Information Table 49. Bio-Thera Solutions Business Overview Table 50. Bio-Thera Solutions TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Bio-Thera Solutions TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 52. Bio-Thera Solutions Recent Developments Table 53. YL Biologics Company Information Table 54. YL Biologics Business Overview Table 55. YL Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. YL Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 57. YL Biologics Recent Developments Table 58. UCB Company Information Table 59. UCB Business Overview Table 60. UCB TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. UCB TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 62. UCB Recent Developments Table 63. Teva Company Information Table 64. Teva Business Overview Table 65. Teva TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Teva TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 67. Teva Recent Developments Table 68. Sandoz Company Information Table 69. Sandoz Business Overview Table 70. Sandoz TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Sandoz TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 72. Sandoz Recent Developments Table 73. Pfizer Company Information Table 74. Pfizer Business Overview Table 75. Pfizer TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Pfizer TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 77. Pfizer Recent Developments Table 78. Janssen Biotech Company Information Table 79. Janssen Biotech Business Overview Table 80. Janssen Biotech TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Janssen Biotech TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 82. Janssen Biotech Recent Developments Table 83. Coherus BioSciences Company Information Table 84. Coherus BioSciences Business Overview Table 85. Coherus BioSciences TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Coherus BioSciences TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 87. Coherus BioSciences Recent Developments Table 88. Celltrion Company Information Table 89. Celltrion Business Overview Table 90. Celltrion TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Celltrion TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 92. Celltrion Recent Developments Table 93. Boehringer Ingelheim Pharmaceuticals Company Information Table 94. Boehringer Ingelheim Pharmaceuticals Business Overview Table 95. Boehringer Ingelheim Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Boehringer Ingelheim Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 97. Boehringer Ingelheim Pharmaceuticals Recent Developments Table 98. Biocon Biologics Company Information Table 99. Biocon Biologics Business Overview Table 100. Biocon Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Biocon Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 102. Biocon Biologics Recent Developments Table 103. Amgen Company Information Table 104. Amgen Business Overview Table 105. Amgen TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Amgen TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 107. Amgen Recent Developments Table 108. AbbVie Company Information Table 109. AbbVie Business Overview Table 110. AbbVie TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. AbbVie TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 112. AbbVie Recent Developments Table 113. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 114. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region (2021-2026) & (K Units) Table 115. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Region (2021-2026) Table 116. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region (2027-2032) & (K Units) Table 117. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Region (2027-2032) Table 118. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Region (2021-2026) & (US$ Million) Table 119. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Region (2021-2026) Table 120. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Region (2027-2032) & (US$ Million) Table 121. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Region (2027-2032) Table 122. North America TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. North America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2021-2026) & (K Units) Table 124. North America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2027-2032) & (K Units) Table 125. North America TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Country (2021-2026) & (US$ Million) Table 126. North America TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Country (2027-2032) & (US$ Million) Table 127. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2021-2026) & (K Units) Table 129. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2027-2032) & (K Units) Table 130. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Country (2021-2026) & (US$ Million) Table 131. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Country (2027-2032) & (US$ Million) Table 132. Asia Pacific TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. Asia Pacific TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2021-2026) & (K Units) Table 134. Asia Pacific TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2027-2032) & (K Units) Table 135. Asia Pacific TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Country (2021-2026) & (US$ Million) Table 136. Asia Pacific TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Country (2027-2032) & (US$ Million) Table 137. South America TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. South America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2021-2026) & (K Units) Table 139. South America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2027-2032) & (K Units) Table 140. South America TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Country (2021-2026) & (US$ Million) Table 141. South America TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Country (2027-2032) & (US$ Million) Table 142. Middle East and Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 143. Middle East and Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2021-2026) & (K Units) Table 144. Middle East and Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2027-2032) & (K Units) Table 145. Middle East and Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Country (2021-2026) & (US$ Million) Table 146. Middle East and Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Country (2027-2032) & (US$ Million) Table 147. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2021-2026) & (K Units) Table 148. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2027-2032) & (K Units) Table 149. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Type (2021-2026) Table 150. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Type (2027-2032) Table 151. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Type (2021-2026) & (US$ Million) Table 152. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Type (2027-2032) & (US$ Million) Table 153. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Type (2021-2026) Table 154. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Type (2027-2032) Table 155. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Price by Type (2021-2026) & (US$/Unit) Table 156. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Price by Type (2027-2032) & (US$/Unit) Table 157. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2021-2026) & (K Units) Table 158. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2027-2032) & (K Units) Table 159. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Application (2021-2026) Table 160. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Application (2027-2032) Table 161. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Application (2021-2026) & (US$ Million) Table 162. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Application (2027-2032) & (US$ Million) Table 163. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Application (2021-2026) Table 164. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Application (2027-2032) Table 165. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Price by Application (2021-2026) & (US$/Unit) Table 166. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Price by Application (2027-2032) & (US$/Unit) Table 167. Key Raw Materials Table 168. Raw Materials Key Suppliers Table 169. TNF Inhibitors for the Treatment of Plaque Psoriasis Distributors List Table 170. TNF Inhibitors for the Treatment of Plaque Psoriasis Customers List Table 171. TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Trends Table 172. TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Drivers Table 173. TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Restraints Table 174. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. TNF Inhibitors for the Treatment of Plaque Psoriasis Product Image Figure 5. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size (2021-2032) & (US$ Million) Figure 7. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (2021-2032) & (K Units) Figure 8. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Average Price (US$/Unit) & (2021-2032) Figure 9. Adalimumab Product Image Figure 10. Certolizumab pegol Product Image Figure 11. Etanercept Product Image Figure 12. Infliximab Product Image Figure 13. Other Product Image Figure 14. Hospital and Clinic Product Image Figure 15. Retail Pharmacies Product Image Figure 16. Other Product Image Figure 17. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Share by Manufacturers in 2025 Figure 18. Global Manufacturers of TNF Inhibitors for the Treatment of Plaque Psoriasis, Manufacturing Sites & Headquarters Figure 19. Global Top 5 and 10 TNF Inhibitors for the Treatment of Plaque Psoriasis Players Market Share by Revenue in 2025 Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 22. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region in 2025 Figure 23. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Region in 2025 Figure 24. North America TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size by Country in 2025 Figure 25. North America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Country (2021-2032) Figure 26. North America TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Country (2021-2032) Figure 27. United States TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Canada TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Mexico TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size by Country in 2025 Figure 31. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Country (2021-2032) Figure 32. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Country (2021-2032) Figure 33. Germany TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. France TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. U.K. TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Italy TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Russia TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Spain TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Netherlands TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Switzerland TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Sweden TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Poland TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Asia Pacific TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size by Country in 2025 Figure 44. Asia Pacific TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Country (2021-2032) Figure 45. Asia Pacific TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Country (2021-2032) Figure 46. China TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Japan TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. South Korea TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. India TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Australia TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Taiwan TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. South America TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size by Country in 2025 Figure 55. South America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Country (2021-2032) Figure 56. South America TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Country (2021-2032) Figure 57. Brazil TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Argentina TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Chile TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Colombia TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Middle East and Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size by Country in 2025 Figure 62. Middle East and Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Country (2021-2032) Figure 63. Middle East and Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Country (2021-2032) Figure 64. Egypt TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. South Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Israel TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Türkiye TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. GCC Countries TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Type (2021-2032) Figure 70. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Type (2021-2032) Figure 71. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Price (US$/Unit) by Type (2021-2032) Figure 72. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Application (2021-2032) Figure 73. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Application (2021-2032) Figure 74. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Price (US$/Unit) by Application (2021-2032) Figure 75. TNF Inhibitors for the Treatment of Plaque Psoriasis Value Chain Figure 76. TNF Inhibitors for the Treatment of Plaque Psoriasis Production Mode & Process Figure 77. Direct Comparison with Distribution Share Figure 78. Distributors Profiles Figure 79. TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Opportunities and Challenges

Scope & coverage.

Types
  • Adalimumab
  • Certolizumab pegol
  • Etanercept
  • Infliximab
  • Other
Applications
  • Hospital and Clinic
  • Retail Pharmacies
  • Other
Companies covered
  • Chia Tai Tianqing Pharmaceutical
  • Innovent Biologics
  • Sino Cell Technologies
  • Samsung Bioepis
  • Hangzhou Bozhirui Biopharmaceuticals
  • Hisun Pharmaceuticals
  • Bio-Thera Solutions
  • YL Biologics
  • UCB
  • Teva
  • Sandoz
  • Pfizer
  • Janssen Biotech
  • Coherus BioSciences
  • Celltrion
  • Boehringer Ingelheim Pharmaceuticals
  • Biocon Biologics
  • Amgen
  • AbbVie

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size (2021-2032)
  4. 2.2.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (2021-2032)
  5. 2.2.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Average Price (2021-2032)
  6. 2.3 TNF Inhibitors for the Treatment of Plaque Psoriasis by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Adalimumab
  9. 2.3.3 Certolizumab pegol
  10. 2.3.4 Etanercept
  11. 2.3.5 Infliximab
  12. 2.3.6 Other
  13. 2.4 TNF Inhibitors for the Treatment of Plaque Psoriasis by Application
  14. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  15. 2.4.2 Hospital and Clinic
  16. 2.4.3 Retail Pharmacies
  17. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue of Manufacturers (2021-2026)
  4. 3.4 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Average Price by Manufacturers (2021-2026)
  5. 3.5 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of TNF Inhibitors for the Treatment of Plaque Psoriasis, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of TNF Inhibitors for the Treatment of Plaque Psoriasis, Product Type & Application
  8. 3.8 Global Manufacturers of TNF Inhibitors for the Treatment of Plaque Psoriasis, Established Date
  9. 3.9 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Chia Tai Tianqing Pharmaceutical
  2. 4.1.1 Chia Tai Tianqing Pharmaceutical Company Information
  3. 4.1.2 Chia Tai Tianqing Pharmaceutical Business Overview
  4. 4.1.3 Chia Tai Tianqing Pharmaceutical TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Chia Tai Tianqing Pharmaceutical TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  6. 4.1.5 Chia Tai Tianqing Pharmaceutical Recent Developments
  7. 4.2 Innovent Biologics
  8. 4.2.1 Innovent Biologics Company Information
  9. 4.2.2 Innovent Biologics Business Overview
  10. 4.2.3 Innovent Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Innovent Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  12. 4.2.5 Innovent Biologics Recent Developments
  13. 4.3 Sino Cell Technologies
  14. 4.3.1 Sino Cell Technologies Company Information
  15. 4.3.2 Sino Cell Technologies Business Overview
  16. 4.3.3 Sino Cell Technologies TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Sino Cell Technologies TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  18. 4.3.5 Sino Cell Technologies Recent Developments
  19. 4.4 Samsung Bioepis
  20. 4.4.1 Samsung Bioepis Company Information
  21. 4.4.2 Samsung Bioepis Business Overview
  22. 4.4.3 Samsung Bioepis TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Samsung Bioepis TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  24. 4.4.5 Samsung Bioepis Recent Developments
  25. 4.5 Hangzhou Bozhirui Biopharmaceuticals
  26. 4.5.1 Hangzhou Bozhirui Biopharmaceuticals Company Information
  27. 4.5.2 Hangzhou Bozhirui Biopharmaceuticals Business Overview
  28. 4.5.3 Hangzhou Bozhirui Biopharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Hangzhou Bozhirui Biopharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  30. 4.5.5 Hangzhou Bozhirui Biopharmaceuticals Recent Developments
  31. 4.6 Hisun Pharmaceuticals
  32. 4.6.1 Hisun Pharmaceuticals Company Information
  33. 4.6.2 Hisun Pharmaceuticals Business Overview
  34. 4.6.3 Hisun Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Hisun Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  36. 4.6.5 Hisun Pharmaceuticals Recent Developments
  37. 4.7 Bio-Thera Solutions
  38. 4.7.1 Bio-Thera Solutions Company Information
  39. 4.7.2 Bio-Thera Solutions Business Overview
  40. 4.7.3 Bio-Thera Solutions TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Bio-Thera Solutions TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  42. 4.7.5 Bio-Thera Solutions Recent Developments
  43. 4.8 YL Biologics
  44. 4.8.1 YL Biologics Company Information
  45. 4.8.2 YL Biologics Business Overview
  46. 4.8.3 YL Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 YL Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  48. 4.8.5 YL Biologics Recent Developments
  49. 4.9 UCB
  50. 4.9.1 UCB Company Information
  51. 4.9.2 UCB Business Overview
  52. 4.9.3 UCB TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 UCB TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  54. 4.9.5 UCB Recent Developments
  55. 4.10 Teva
  56. 4.10.1 Teva Company Information
  57. 4.10.2 Teva Business Overview
  58. 4.10.3 Teva TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Teva TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  60. 4.10.5 Teva Recent Developments
  61. 4.11 Sandoz
  62. 4.11.1 Sandoz Company Information
  63. 4.11.2 Sandoz Business Overview
  64. 4.11.3 Sandoz TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Sandoz TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  66. 4.11.5 Sandoz Recent Developments
  67. 4.12 Pfizer
  68. 4.12.1 Pfizer Company Information
  69. 4.12.2 Pfizer Business Overview
  70. 4.12.3 Pfizer TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Pfizer TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  72. 4.12.5 Pfizer Recent Developments
  73. 4.13 Janssen Biotech
  74. 4.13.1 Janssen Biotech Company Information
  75. 4.13.2 Janssen Biotech Business Overview
  76. 4.13.3 Janssen Biotech TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Janssen Biotech TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  78. 4.13.5 Janssen Biotech Recent Developments
  79. 4.14 Coherus BioSciences
  80. 4.14.1 Coherus BioSciences Company Information
  81. 4.14.2 Coherus BioSciences Business Overview
  82. 4.14.3 Coherus BioSciences TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Coherus BioSciences TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  84. 4.14.5 Coherus BioSciences Recent Developments
  85. 4.15 Celltrion
  86. 4.15.1 Celltrion Company Information
  87. 4.15.2 Celltrion Business Overview
  88. 4.15.3 Celltrion TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Celltrion TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  90. 4.15.5 Celltrion Recent Developments
  91. 4.16 Boehringer Ingelheim Pharmaceuticals
  92. 4.16.1 Boehringer Ingelheim Pharmaceuticals Company Information
  93. 4.16.2 Boehringer Ingelheim Pharmaceuticals Business Overview
  94. 4.16.3 Boehringer Ingelheim Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Boehringer Ingelheim Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  96. 4.16.5 Boehringer Ingelheim Pharmaceuticals Recent Developments
  97. 4.17 Biocon Biologics
  98. 4.17.1 Biocon Biologics Company Information
  99. 4.17.2 Biocon Biologics Business Overview
  100. 4.17.3 Biocon Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Biocon Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  102. 4.17.5 Biocon Biologics Recent Developments
  103. 4.18 Amgen
  104. 4.18.1 Amgen Company Information
  105. 4.18.2 Amgen Business Overview
  106. 4.18.3 Amgen TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Amgen TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  108. 4.18.5 Amgen Recent Developments
  109. 4.19 AbbVie
  110. 4.19.1 AbbVie Company Information
  111. 4.19.2 AbbVie Business Overview
  112. 4.19.3 AbbVie TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 AbbVie TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  114. 4.19.5 AbbVie Recent Developments
5 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Scenario by Region
  1. 5.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region: 2021-2032
  3. 5.2.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region: 2021-2026
  4. 5.2.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region: 2027-2032
  5. 5.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Region: 2021-2032
  6. 5.3.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Region: 2021-2026
  7. 5.3.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Region: 2027-2032
  8. 5.4 North America TNF Inhibitors for the Treatment of Plaque Psoriasis Market Facts & Figures by Country
  9. 5.4.1 North America TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2021-2032)
  11. 5.4.3 North America TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Market Facts & Figures by Country
  16. 5.5.1 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2021-2032)
  18. 5.5.3 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific TNF Inhibitors for the Treatment of Plaque Psoriasis Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America TNF Inhibitors for the Treatment of Plaque Psoriasis Market Facts & Figures by Country
  41. 5.7.1 South America TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2021-2032)
  43. 5.7.3 South America TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.7.7 Colombia
  48. 5.8 Middle East and Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Market Facts & Figures by Country
  49. 5.8.1 Middle East and Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size by Country: 2021 VS 2025 VS 2032
  50. 5.8.2 Middle East and Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2021-2032)
  51. 5.8.3 Middle East and Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Country (2021-2032)
  52. 5.8.4 Egypt
  53. 5.8.5 South Africa
  54. 5.8.6 Israel
  55. 5.8.7 Türkiye
  56. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2021-2032)
  2. 6.1.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Type (2021-2032)
  4. 6.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Type (2021-2032)
  5. 6.2.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Type (2021-2032)
  7. 6.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2021-2032)
  2. 7.1.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Application (2021-2032)
  4. 7.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Application (2021-2032)
  5. 7.2.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Application (2021-2032)
  7. 7.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 TNF Inhibitors for the Treatment of Plaque Psoriasis Value Chain Analysis
  2. 8.1.1 TNF Inhibitors for the Treatment of Plaque Psoriasis Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 TNF Inhibitors for the Treatment of Plaque Psoriasis Production Mode & Process
  5. 8.2 TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 TNF Inhibitors for the Treatment of Plaque Psoriasis Distributors
  8. 8.2.3 TNF Inhibitors for the Treatment of Plaque Psoriasis Customers
9 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Analyzing Market Dynamics
  1. 9.1 TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Trends
  2. 9.2 TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Drivers
  3. 9.3 TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Opportunities and Challenges
  4. 9.4 TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.
      Talk to an analyst